195 related articles for article (PubMed ID: 28811486)
1. Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging.
Shah A; Delgado-Goni T; Casals Galobart T; Wantuch S; Jamin Y; Leach MO; Robinson SP; Bamber J; Beloueche-Babari M
Sci Rep; 2017 Aug; 7(1):8215. PubMed ID: 28811486
[TBL] [Abstract][Full Text] [Related]
2. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
Joshi SS; Jiang S; Unni E; Goding SR; Fan T; Antony PA; Hornyak TJ
PLoS One; 2018; 13(2):e0191264. PubMed ID: 29481571
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models.
Smyth T; Paraiso KHT; Hearn K; Rodriguez-Lopez AM; Munck JM; Haarberg HE; Sondak VK; Thompson NT; Azab M; Lyons JF; Smalley KSM; Wallis NG
Mol Cancer Ther; 2014 Dec; 13(12):2793-2804. PubMed ID: 25349308
[TBL] [Abstract][Full Text] [Related]
4. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
5. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
6. Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.
Beloueche-Babari M; Arunan V; Jackson LE; Perusinghe N; Sharp SY; Workman P; Leach MO
Oncotarget; 2010 Jul; 1(3):185-97. PubMed ID: 21037799
[TBL] [Abstract][Full Text] [Related]
7. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
8. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
9. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF
Mielczarek-Lewandowska A; Sztiller-Sikorska M; Osrodek M; Czyz M; Hartman ML
Apoptosis; 2019 Aug; 24(7-8):596-611. PubMed ID: 30989459
[TBL] [Abstract][Full Text] [Related]
10. Combined BRAF and HSP90 Inhibition in Patients with Unresectable
Eroglu Z; Chen YA; Gibney GT; Weber JS; Kudchadkar RR; Khushalani NI; Markowitz J; Brohl AS; Tetteh LF; Ramadan H; Arnone G; Li J; Zhao X; Sharma R; Darville LNF; Fang B; Smalley I; Messina JL; Koomen JM; Sondak VK; Smalley KSM
Clin Cancer Res; 2018 Nov; 24(22):5516-5524. PubMed ID: 29674508
[No Abstract] [Full Text] [Related]
11. A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas.
Sanchez JN; Subramanian C; Chanda M; Shanguan G; Zhang N; Wang T; Timmermann BN; Blagg BSJ; Cohen MS
Melanoma Res; 2021 Jun; 31(3):197-207. PubMed ID: 33904516
[TBL] [Abstract][Full Text] [Related]
12. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
[TBL] [Abstract][Full Text] [Related]
13. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN
J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239
[TBL] [Abstract][Full Text] [Related]
14. BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.
Borst A; Haferkamp S; Grimm J; Rösch M; Zhu G; Guo S; Li C; Gao T; Meierjohann S; Schrama D; Houben R
Cancer Lett; 2017 Sep; 404():70-78. PubMed ID: 28720543
[TBL] [Abstract][Full Text] [Related]
15.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
16. MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.
Caenepeel S; Cooke K; Wadsworth S; Huang G; Robert L; Moreno BH; Parisi G; Cajulis E; Kendall R; Beltran P; Ribas A; Coxon A; Hughes PE
Oncotarget; 2017 Mar; 8(11):17795-17809. PubMed ID: 28147313
[TBL] [Abstract][Full Text] [Related]
17. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
18. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
[TBL] [Abstract][Full Text] [Related]
19. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
Xiao J; Egger ME; McMasters KM; Hao H
BMC Cancer; 2018 Jun; 18(1):675. PubMed ID: 29929490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]